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Open access under CC BBacterial over-expression of kinases is often associated with high levels of auto-phosphorylation result-
ing in heterogeneous recombinant protein preparations or sometimes in insoluble protein. Here we pres-
ent expression systems for nine kinases in Escherichia coli and, for the most heavily phosphorylated, the
characterisation of factors affecting auto-phosphorylation. Experiments showed that the level of auto-
phosphorylation was proportional to the rate of expression. Comparison of phosphorylation states fol-
lowing in vitro phosphorylation with phosphorylation states following expression in E. coli showed that
the non-physiological ‘hyper-phosphorylation’ was occurring at sites that would require local unfolding
to be accessible to a kinase active site. In contrast, auto-phosphorylation on unphosphorylated kinases
that had been expressed in bacteria overexpressing k-phosphatase was only observed on distinct exposed
sites. Remarkably, the Ser/Thr kinase PLK4 auto-phosphorylated on a tyrosine residue (Tyr177) located in
the activation segment. The results give support to a mechanism in which auto-phosphorylation occurs
before or during protein folding. In addition, the expression systems and protocols presented will be a
valuable resource to the research community.
 2011 Elsevier Inc. .Open access under CC BY license.Introduction
Kinases are extensively studied drug targets, but reagents for
these investigations are not widely distributed or always afford-
able. In particular the availability of high-yielding validated bacte-
rial expression systems for human protein kinases is limited. We
present bacterial expression and protein puriﬁcation methods for
nine human protein kinases using the convenient hexahistidine
tag method. The structures of all of these proteins have been deter-
mined and deposited in the protein data bank (PDB). However, in
some cases there is no literature report of expression and puriﬁca-
tion protocols, and in some other cases the protein was produced
with an alternative puriﬁcation tag (thioredoxin or glutathione
S-transferase (GST)).1 The kinases presented here are:
Mitogen-activated protein kinase 13 (MAPK13, also known as
p38d), which is a key molecule in MAPK signalling. Among thes).
; MAPK13, mitogen-activated
4; MAPK3, mitogen-activated
kinase 8; MAP2K2, mitogen-
ss responsive 1; TCEP, tris(2-
ﬂuoride; IMAC, immobilised
tion time-of-ﬂight; FA, formic
2,5-dihydroxybenzoic acid.
Y license.functions recently identiﬁed for p38d speciﬁcally is a role in skin
tumour development [1]. The structure of MAPK13 has been re-
cently made available by SGX Pharmaceuticals Inc. (PDB ID:
3COI). The same group also released the structure of the kinase do-
main of polo-like kinase 4 (PLK4, also known as STK18) which is in-
volved in centriole duplication [2] (PDB ID: 3COK) and the
structure of serine/threonine kinase 24 (STK24, also known as
MST3), a key enzyme in the regulation of cell death (PDB IDs:
3CKW, 3CKX). The structure of STK24 has also been determined
using protein produced with a thioredoxin tag expression system
at extra-low temperatures [3].
Mitogen-activatedprotein kinase3 (MAPK3, also knownas ERK1)
is involved in regulation of meiosis and mitosis. The structure of
MAPK3 has been determined, utilising a GST fusion construct
expressed in Escherichia coli [4]. Mitogen-activated protein kinase 8
(MAPK8, alsoknownas JNK) is involved instress response. Tocrystal-
lize the beta 1 isoform (NCBI Ref. NP_620634.1), Heo et al. expressed
the protein as a C-terminal hexahistidine fusion in E. coli [5]. A selec-
tionof structures ofMAPK8 isoformalpha 1 (NCBI Ref. NP_002741.1)
incomplexwithdifferent compoundshavebeenpublishedbyAbbott
Laboratories [6–9] using a C-terminal hexahistidine fusion (experi-
mental details not published), and byGlaxoSmithKline, fromprotein
producedasanN-terminalGST fusion inE. coli [10], expressionmeth-
ods also unpublished. We present expression of MAPK8 isoform
alpha1 as an N-terminal hexahistidine fusion in E. coli.
A. Shrestha et al. / Protein Expression and Puriﬁcation 81 (2012) 136–143 137Mitogen-activated protein kinase kinase 2 (MAP2K2, also
known as MEK2), along with MAP2K1 (MEK1) is the upstream ki-
nase of ERK. The structure of MAP2K2 has been determined (PDB
ID: 1S9I), utilising a C-terminal hexahistidine fusion [11]. Oxida-
tive-stress responsive 1 (OSR1, also known as OXSR1) is involved
in regulation of Na+/K+/2Cl transporters. The structure of OSR1
has been determined using an N-terminal hexahistidine tag [12],
as in our construct presented here. Mitogen-activated protein ki-
nase 9 (MAPK9, also known as JNK2) is involved in stress response.
The structure of MAPK9 has been determined by Roche (PDB ID:
3E7O), from bacterially expressed protein [13]. CHK2 checkpoint
homologue (CHEK2) is involved regulation of the cell cycle follow-
ing DNA damage. Various structures of CHEK2 have been deter-
mined, both with [14] and without the N-terminal FHA domain
[15,16]. In each case the construct was also C-terminally truncated.
Here we present nine bacterial expression systems using hexa-
histidine tags for protein puriﬁcation, including analysis of their
phosphorylation states by mass spectroscopy. For the three most
phosphorylated proteins, expression trials at different growth and
induction conditions showed that heterogeneous auto-phosphory-
lation can be signiﬁcantly inﬂuenced by expression protocols, while
co-expression of k-phosphatase yielded homogeneously non-phos-
phorylated protein. Our data suggest that phosphorylation events
during expression can occur at non-physiological sites that are
not accessible as substrate sites in folded proteins.
Materials and methods
Cloning
DNA for each of the proteins was ampliﬁed by PCR from tem-
plate DNA obtained from a variety of sources. For MAPK13, MAPK3,
PLK4, MAP2K2 and MAPK9, DNA was obtained from the Mamma-
lian Gene Collection. The IMAGE Consortium Clone IDs for
MAPK13, MAPK3, PLK4, MAP2K2 and MAPK9 are 2819932,
3634492, 5273226, 2961198 and 5528624, respectively. STK24
was obtained from synthetic DNA. MAPK8 and OSR1 were obtained
from commercial sources, and CHEK2 DNA was generously do-
nated by the National Institute for Medical Research, London, UK.
PCR primers included appropriate 50 extensions for subsequent
incorporation into expression vectors.
The PCR products were incorporated into home-made expres-
sion vectors [17] by ligation-independent cloning as detailed in Ta-
ble 1. All constructs contained either an N-terminal or C-terminal
hexahistidine tag. All of the vectors used contained a TEV protease
recognition site for removal of the tag except pNIC-CH where the
hexa-histidine tag is non-cleavable. Full DNA sequences of all of
the constructs and the translated protein sequences are available
in the Supplementary material.
Expression
The plasmids were transformed into E. coli BL21 (DE3) cells
containing the pRARE2 plasmid from commercial Rosetta II (DE3)Table 1
Expression constructs. Vector information has been recently published [17].
Target GenBank ID Residue Range Vector
MAPK13 4506085 15–359 pLIC-SGC1
MAPK3 38257141 1–379 pLIC-SGC1
MAPK8 4506095 1–363 pLIC-SGC1
PLK4 21361433 1–341 pNIC-CH
MAP2K2 13489054 46–400 pNIC-CTHF
OSR1 4826878 1–309 pNIC28-Bsa4
STK24 20070158 31–301 pNIC28-Bsa4
MAPK9 21237736 1–380 pNIC-CH
CHEK2 6005850 185–543 pNIC28-Bsa4cells. The transformed cells were used to inoculate 10 ml of LB
medium containing 34 lg/ml chloramphenicol and either 50 lg/
ml kanamycin or 100 lg/ml ampicillin, and these cultures were
grown overnight with shaking at 37 C. The next day, the 10 ml
culture was used to inoculate 1 l of LB medium containing either
40 lg/ml kanamycin or 80 lg/ml ampicillin in a 2 l bafﬂed shaker
ﬂask. The cultures were grown with shaking at 37 C until an OD600
of 0.50–0.68 was reached. The temperature was then reduced to
20 C and protein expression was induced by addition of 0.5 mM
isopropyl-b-D-thiogalactopyranoside. Cells were grown overnight
before harvesting by centrifugation. Each cell pellet was resus-
pended in 20 ml binding buffer (50 mM Hepes pH 7.4, 500 mM
NaCl, 5% glycerol, 5 mM imidazole, 0.5 mM tris(2-carboxy-
ethyl)phosphine (TCEP), 0.2 mM phenylmethylsulfonyl ﬂuoride
(PMSF)) and lysed by sonication. The insoluble debris was removed
by centrifugation.
Protein puriﬁcation
The target proteins were puriﬁed from the clariﬁed cell extracts
by immobilised metal ion chromatography (IMAC): Each cell ex-
tract was passed through 1 ml of Ni2+ resin in a gravity-ﬂow col-
umn, and the resin was then washed with 20 ml of binding
buffer, 10 ml of binding buffer containing 25 mM imidazole. Pro-
tein was eluted with 5 ml of binding buffer containing 250 mM
imidazole. Each 5 ml eluted fraction was further puriﬁed on an
S200 16/60 gel ﬁltration column (GE Healthcare) pre-equilibrated
in 20 mM Hepes pH 7.4, 500 mM NaCl, 0.5 mM TCEP. Gel ﬁltration
retention volumes are listed in Table 2. For the proteins with a TEV
protease recognition site for tag cleavage, removal of the hexahis-
tidine tag was accomplished by addition of TEV protease and incu-
bation at 4 C overnight.
In vitro auto-phosphorylation
Protein samples were incubated for 1 h at room temperature
with 1 mM ATP, 2 mM MgCl2 and 1 mM sodium orthovanadate.
When MnCl2 was also added, the concentration was 1 mM.
In vitro dephosphorylation
Protein samples were incubated overnight at room temperature
with 1 mMMnCl2 and approximately 0.02 molar ratio of k-phos-
phatase (puriﬁed by GST-afﬁnity from bacterial over-expression).
Mass spectrometry
Intact mass measurements were acquired on an Agilent electro-
spray-ionisation time-of-ﬂight (ESI-TOF) mass spectrometer
attached to an Agilent liquid chromatography system using a C3 re-
verse-phase column. Proteins were separated from small molecules
on the liquid chromatography system in0.1% formic acid (FA) buffer,
eluting with a methanol gradient, before injection into ESI-TOF.Puriﬁcation Tag Protease for tag cleavage Antibiotic resistance
N-terminal His6 TEV Ampicillin
N-terminal His6 TEV Ampicillin
N-terminal His6 TEV Ampicillin
C-terminal His6 – Kanamycin
C-terminal His6 TEV Kanamycin
N-terminal His6 TEV Kanamycin
N-terminal His6 TEV Kanamycin
C-terminal His6 – Kanamycin
N-terminal His6 TEV Kanamycin
Table 2
Protein puriﬁcation and mass spectrometry analysis. Gel ﬁltration experiments were performed on four separate S200 16/60 columns and the observed retention volumes
correspond to the molecular weights of the monomers. Deviations in retention volume are within the range expected for monomeric proteins of the molecular weights indicated.
By comparison with molecular weight standards, a dimeric protein of 40 kDa MWwould be expected to give a retention volume <75 ml under equivalent conditions. For the mass
spectrometry analysis, the range is the minimum and maximum number of phosphorylations observed by mass spectrometry, and the modal value is the most highly populated
phosphorylation state.
Target Expected molecular
mass (Da)
Gel ﬁltration
retention volume (ml)
Protein yield
(mg/l culture)
Observed mass (Da) Additional peaks Interpretation/range of
phosphorylations
MAPK13 42405.7 87 9.0 42408.0 None Correct
MAPK3 45688.4 85 5.0 45690.9 1 Phosphorylation Correct/range: 0–1
Modal value: 0
MAPK8 44464.5 85 14.7 44472.4 1 Phosphorylation Correct/range: 0–1
Modal value: 0
PLK4 39130 95 27.0 39639.6 9–16 Phosphorylation Loss of N-terminal Met/range:
8–16
Modal value: 13
MAP2K2 42515.7 80 2.4 42518.8 None Correct
OSR1 37168.9 83 20.3 37171.1 None Correct
STK24 33257.1 84 4.0 33339.4 2–6 Phosphorylation Correct/range: 1–6
Modal value: 3
MAPK9 44615.5 80 36.7 44487.5 None Loss of N-terminal Met
CHEK2 40835.1 85 25.8 40917.2 2–4 Phosphorylation Correct/range: 1–4
Modal value: 2
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sample, diluted in 100 mM NH4HC03, was reduced (10 mM dithi-
othreitol, 56 C, 40 min) and alkylated (40 mM iodoacetamide, RT,
20 min) prior to overnight digestion at 37 C with trypsin or
chymotrypsin (Promega) at a ﬁnal concentration of 5 lg/ml.
The digest was stopped by reducing the pH to less than 3.0 with
FA. Digested peptides were evaporated to dryness and resus-
pended in 2% triﬂuoroacetic acid (TFA), 70% acetonitrile (ACN).
Phosphopeptides were enriched on titanium dioxide beads
(10 lM titansphere, GL Sciences, Japan) pre-washed in 80%
ACN, 2% TFA, 3 mg/ml 2,5-dihydroxybenzoic acid (DHB). The
beads were washed with 2% ACN, 0.1% FA. Non-phosphopeptides
were eluted with 80% ACN, 0.1% TFA, 300 mg/ml DHB before
washing in 80% ACN 0.1% TFA. Phosphopeptides were eluted in
40% ACN, 15% aqueous NH4OH, evaporated to dryness and resus-
pended in 2% ACN, 0.1% FA. Phosphopeptides were analysed by
online nanoﬂow liquid chromatography tandem mass spectrome-
try using a Dionex U300 (ﬁtted with a Pepmap C18 column and
eluted with a linear gradient of ACN) connected to a Bruker
HCTultra ETD II ion trap through a nanoelectrospray ion source.
The top four ions present in the survey scan were automatically
selected for fragmentation by ETD. Alternatively ETD fragmenta-
tion was triggered by neutral loss of the phosphate group (loss
of m/z 32.7, 38.7, 49.0, 58) in CID mode. Phosphopeptides were
identiﬁed by Mascot (Matrix Science) searches of all tandem
mass spectra against SwissProt.Results
Construct design and expression analysis
For each target, a selection of bacterial expression constructs
were designed, covering different ranges of the target kinase do-
main by using different N- and C-terminal truncations. These con-
structs were cloned into pET-based vectors carrying sequences for
hexahistidine tags, transformed into an E. coli protein expression
strain, and evaluated on a small scale for expression level of the
target protein (results not shown). In some cases both N- and C-
terminal hexahistidine tagged constructs were evaluated. A con-
struct of each target that had among the highest yield of soluble
protein expression is listed in Table 1 and illustrated in Fig. 1.Protein puriﬁcation
To conﬁrm the production of soluble protein and to evaluate the
suitability of each construct for further work, each construct was
expressed in 1 l of bacterial culture. Proteins were puriﬁed from
the lysed cells by Ni2+ afﬁnity chromatography followed by size-
exclusion chromatography (Table 2). Equal amounts of each puri-
ﬁed protein were run on a reducing, denaturing SDS–PAGE gel
(Fig. 2), which showed all of the proteins migrating as an intact
protein at the expected size. Only the STK24 gel sample showed
the possibility of a limited amount of degradation or proteolysis
(Fig. 2). The reported expression systems yielded 2.4–36 mg of
pure recombinant protein per litre of culture medium.Protein characterisation
The size-exclusion chromatography showed that all of the pro-
teins were monomeric in solution (Table 2), without signiﬁcant
levels of aggregation (chromatograms not shown). Electrospray
(ESI) mass spectrometry analysis of the proteins was performed
before and after removal of the hexahistidine tag (Tables 2 and
3). The results showed that all of the constructs expressed protein
of the expected molecular weight, with the exception of MAPK9
and PLK4 where the difference in mass can be attributed to loss
of an N-terminal methionine residue.
Five proteins were phosphorylated (Tables 2 and 3), most nota-
bly PLK4 which showed a range of phosphorylation states up to 16
phosphorylations, depending on the experiment (Fig. 3). In the case
of STK24, the difference of up to six phosphorylations with the
hexa-histidine tag (which also contained linker residues and a
TEV protease cleavage site), and only up to three without the tag,
does not necessarily imply that the tag was triply phosphorylated,
as a difference in ionisability between the two samples could
potentially account for a difference in measurement sensitivity.
Nevertheless, it is likely that at least some of the three removed
phosphorylations were on the tag, whose sequence contains three
serine and one threonine residues.
The phosphorylation sites for the two most heavily phosphory-
lated proteins, PLK4 and CHEK2, were mapped by proteolytic
digestion followed by mass spectrometry (Tables 7 and 8). These
sites were mapped onto the available crystal structures of these
Fig. 2. SDS–PAGE gel of protein samples following gel ﬁltration chromatography.
Standard molecular weight markers were Precision Plus from BioRad (M); the
numbers in the vertical scale on the left show the mass in kDa. Each sample lane
was loaded with 2 lg of protein from the pooled gel ﬁltration chromatography
fractions that had been boiled in the presence of sodium dodecyl sulphate. The gel
was visualised by Coomassie blue staining.
Fig. 1. Domains present in each of the nine proteins in this study. For each protein the residue range covered by the expression construct in this study is illustrated above the
domain diagram. Domain ranges were taken from analysis against the Pfam database [23].
A. Shrestha et al. / Protein Expression and Puriﬁcation 81 (2012) 136–143 139proteins (Fig. 4A and D). The sites were all on the surface of the
protein, although many sites would clearly require local unfolding
to bind to a kinase active site. Some of the sites could not be
mapped onto the structures as they were on parts of the protein
that were disordered in the structures, such as the kinase activa-
tion loop or the C-terminus of the protein.Dependence of phosphorylation level on experimental conditions
To investigate the hypothesis that the observed hyper-phos-
phorylation is non-physiological and is caused by the rapid over-
expression of the kinases in a strong expression system, leading
to phosphorylation of proteins before or during protein folding,
experiments were designed to vary the rate of expression. PLK4,
CHEK2 and STK24 were expressed with a low or high concentration
of the induction agent IPTG, and with the induction taking place at
37 or 20 C (Table 4).The experiments showed that lower temperature at the time of
induction reduced both the maximum number of phosphorylation
sites and the number of phosphorylations in the most common
phosphorylation state (modal phosphorylation state), while a
reduction in the IPTG concentration also reduced both the maxi-
mum number and the mode. Therefore the differences observed
were not solely due to differing enzyme efﬁciency with tempera-
ture. Additional experiments were performed without adding any
IPTG; in all cases no protein was detectable on Coomasie-stained
SDS–PAGE gels (data not shown), eliminating the possibility that
the results were affected by ‘leaky’ expression of protein in the ab-
sence of inducer.
In vitro auto-phosphorylation, following co-expression with k-
phosphatase
To test further the hypothesis that the observed hyper-phos-
phorylation during E. coli over-expression is non-physiological,
in vitro auto-phosphorylation experiments were performed on
PLK4, CHEK2 and STK24, starting with non-phosphorylated pro-
teins. The constructs for PLK4, CHEK2 and STK24 were transformed
into cells containing a k-phosphatase expression plasmid. This co-
plasmid also contained genes for the rare E. coli tRNAs. The expres-
sions were repeated, and the phosphorylation state of the resultant
proteins analysed by mass spectrometry. For all three proteins, co-
expression with k-phosphatase completely eliminated all phos-
phorylations (data not shown). Furthermore, in the case of STK24
the yield of soluble protein was substantially higher than when ex-
pressed without k-phosphatase co-expression (data not shown).
These non-phosphorylated proteins were used for in vitro auto-
phosphorylation experiments. The proteins were reacted with ATP
andMg2+,with orwithout the addition ofMn2+, for one hour at room
temperature (equivalent to the 20 C used for protein expression).
Sodium vanadate was added to inactivate any trace amount of k-
phosphatase that might have remained in the puriﬁed protein. The
result of the auto-phosphorylation experiments can be seen in Table
5. In each case, both themaximumnumber of phosphorylation sites
and themodal value are reduced following in vitro phosphorylation,
Table 3
Mass spectrometry analysis of proteins after removal of the hexahistidine tag. The range is the minimum and maximum number of phosphorylations observed by mass
spectrometry, and the modal value is the most highly populated phosphorylation state. The hexahistidine tag for PLK4 and MAPK9 was non-removable so these proteins do not
feature in this table.
Target Expected molecular mass (Da) Observed mass (Da) Additional peaks Interpretation/range of phosphorylations
MAPK13 39940.1 39942.3 None Correct
MAPK3 43222.8 43225.1 1 Phosphorylation Correct/range: 0–1
Modal value: 0
MAPK8 41998.9 42001.6 1 Phosphorylation Correct/range: 0–1
Modal value: 0
MAP2K2 40610.8 40613.6 None Correct
OSR1 34703.3 34705.2 None Correct
STK24 30791.5 30793.2 1–3 Phosphorylation Correct/range: 0–3
Modal value: 1
CHEK2 38369.5 38451.2 2–4 Phosphorylation Correct/range: 1–4
Modal value: 1
Fig. 3. Example mass spectra of PLK4 following expression in E. coli. (A) Following expression without co-expressed k-phosphatase. The peaks correspond to a range of
phosphorylations from 8 to 16. (B) Following co-expression with k-phosphatase. The peak corresponds to the molecular weight of the intact protein, minus an N-terminal
methionine, with no phosphorylations.
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phosphatase.
For PLK4 these phosphorylation sites were also mapped by
mass spectrometry (Table 8), which identiﬁed the location of three
of the potential ﬁve positions. Two of the positions were on the ki-
nase activation loop, including the activation residue Thr170,
which is disordered in the available crystal structure, and one
(Ser22) was on the glycine-rich loop of the kinase domain which
is also generally ﬂexible in the absence of a bound nucleotide or
inhibitor (Fig. 4B).
In vitro dephosphorylation, following E. coli expression auto-
phosphorylation
The phosphorylated proteins produced by expression in E. coli
without k-phosphatase co-expression (Tables 2 and 3) were used
for in vitro dephosphorylation experiments. The proteins were
incubated with glutathione-S-transferase (GST) tagged k-phospha-tase in the presence of Mn2+. In each case the proteins remained
phosphorylated, although with a reduction in the number of phos-
phorylated sites following the reaction (Table 6).
For CHEK2 and PLK4 these phosphorylation sites that were not
removed by the k-phosphatase treatment in vitro were again
mapped by mass spectrometry (Tables 7 and 8, and Fig. 4C and
E). The results showed that in each case the phosphatase removed
all of the phosphorylations that were on the C-terminal lobe of the
kinase domain while leaving most of the sites on the N-terminal
lobe, including those on the activation loop.
Discussion
Many kinases auto-phosphorylate during heterologous expres-
sion, and often an excessive number of phosphorylation states
are observed (hyper-phosphorylation). This is a well-known obser-
vation and the additional phosphorylations can sometimes cause
problems for subsequent applications of the puriﬁed proteins, for
Fig. 4. Phosphorylation sites of PLK4 and CHEK2 mapped onto the available crystal structures of these proteins (PDB IDs 3COK and 3I6 W). (A) Phosphorylation sites of PLK4
following expression in E. coli. (B) Phosphorylation sites of PLK4 following in vitro auto-phosphorylation. (C) Phosphorylation sites of PLK4 following in vitro de-
phosphorylation of hyper-phosphorylated protein from E. coli expression. (D) Phosphorylation sites of CHEK2 following expression in E. coli. (E) Phosphorylation sites of
CHEK2 following in vitro de-phosphorylation of hyper-phosphorylated protein from E. coli expression.
Table 4
Comparison of phosphorylation status under different expression conditions. The
range is the minimum and maximum number of phosphorylations observed by mass
spectrometry, and the modal value is the most highly populated phosphorylation
state.
Temp. at
induction
[IPTG]
37 C 20 C
0.05 mM 0.5 mM 0.05 mM 0.5 mM
PLK4 Range: 5–10 Range: 8–16* Range: 3–9 Range: 4–9
Modal
value: 8
Modal value:
13*
Modal
value: 6
Modal
value: 7
CHEK2 Range: 2–5 Range: 2–5 Range: 0–4 Range: 0–5
Modal
value: 4
Modal value:
4
Modal
value: 1
Modal
value: 3
STK24 Range: 0–3 Range: 1–5 Range: 0–2 Range: 1–5
Modal
value:1
Modal value:
2
Modal
value: 0
Modal
value: 2
* Result from Table 2, the protein from the 50 ml scale expression under these
conditions did not give a high quality mass spectrum.
Table 5
Phosphorylation state following in vitro auto-phosphorylation of protein co-expressed
with k-phosphatase. The range is the minimum and maximum number of phospho-
rylations observed by mass spectrometry, and the modal value is the most highly
populated phosphorylation state.
Auto-phosphorylation with
ATP and Mg2+
Auto-phosphorylation with ATP,
Mg2+ and Mn2+
PLK4 Range: 0–5 Range: 1–4
Modal value: 1 Modal value: 3
CHEK2 Range: 0 Range: 0
Modal value: 0 Modal value: 0
STK24 Range: 0 Range: 0
Modal value: 0 Modal value: 0
Table 6
Phosphorylation state following in vitro dephosphorylation with k-phosphatase of
protein expressed in E. coli without phosphatase co-expression. The range is the
minimum and maximum number of phosphorylations observed by mass spectrom-
etry, and the modal value is the most highly populated phosphorylation state.
Dephosphorylation with k-phosphatase
PLK4 Range: 0–6
Modal value: 1
CHEK2 Range: 0–2
Modal value: 0
STK24 Range: 1–4
Modal value: 3
Table 7
Locations of phosphorylation sites in CHEK2 as determined by proteolytic digestion
followed by mass spectrometry. Underlined sites are in parts of the protein visible in
the available structures.
CHEK2 Auto-
phosphorylation
in E. coli
Auto-
phosphorylation
in vitro
Remaining sites
after
dephosphorylation
Trypsin digest Thr225 Thr225
Ser228 Ser228
Ser260 Ser260
Thr378 Thr378
Ser379 Ser379
Ser506
Thr507
Ser516
Thr517
Ser518
Thr532
Thr533
Chymotrypsin
digest
Ser260
Thr272
Thr383
A. Shrestha et al. / Protein Expression and Puriﬁcation 81 (2012) 136–143 141example if phosphorylations on a puriﬁcation tag cause proteolytic
tag removal to fail [18] or if phosphorylations occur on interfaces
used to bind partner proteins. One hypothesis is that following
induction, as the cell is being ﬂooded with recombinant protein
produced by a strong promoter, phosphorylations are introduced
to the newly-translated protein during folding. In this way, phos-
phorylations are introduced to sites that are either not surface-ex-
posed at all or, as observed here, that are otherwise non-reactive.
These phosphorylations are sometimes not removed by subse-quent in vitro phosphatase treatment, and cannot be replicated
by in vitro auto-phosphorylation experiments.
The results on PLK4, CHEK2 and STK24 support this hypothe-
sis, since a reduction in the rate of protein production (either
through reduced inducer concentration or reduced temperature)
lead to a reduction in the level of phosphorylation. The in vitro
phosphorylation and dephosphorylation experiments also support
Table 8
Locations of phosphorylation sites in PLK4 as determined by proteolytic digestion
followed by mass spectrometry. Underlined sites are in parts of the protein visible in
the available structures.
PLK4 Auto-
phosphorylation
in E. coli
Auto-
phosphorylation
in vitro
Remaining sites
after
dephosphorylation
Trypsin digest Ser22 Ser22 Ser22
Tyr27
Thr138 Thr138
Ser140 Ser140
Thr159
Tyr169
Thr170 Thr170
Thr174 Thr174
Tyr177 Tyr177 Tyr177
Ser179 Ser179
Thr184
Tyr228
Ser232
Ser235
Ser255
Ser257
Ser258
Ser284
Thr323
Chymotrypsin
digest
Thr3 Thr3
Ser22
Thr184
Ser186
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icantly less phosphorylation in all cases as E. coli expression, and
in vitro dephosphorylation (in the case of CHEK2) did not remove
all of the phosphorylations introduced during E. coli expression.
The phosphorylation mapping on PLK4 and CHEK2 showed that
for auto-phosphorylation, the large number of sites phosphory-
lated during expression in E. coli are located all over the surface
of the protein, and many of these sites while not completely ‘bur-
ied’ in the protein interior would nevertheless require local unfold-
ing to bind to a kinase active site. In vitro, however, only sites on
the N-terminal lobe of the kinase were phosphorylated, although
there were two unidentiﬁed sites which could have been located
elsewhere. It is important to point out that the expressions were
performed at similar temperatures to the auto-phosphorylation
experiments (20 C vs. room temperature) and so temperature-
dependent ﬂexibility was not a factor. In contrast, during in vitro
dephosphorylation the sites that were removed were all on the
C-terminal lobe, showing that the kinases and the k-phosphatase
have very different substrate recognition proﬁles. Considering that
the N-terminal lobe of protein kinases is generally considered to
more ﬂexible than the C-terminal lobe, this contrast in behaviour
of auto-phosphorylation compared to lambda-phosphatase speci-
ﬁcity is interesting and could be connected in some way to known
mechanisms of trans-activation of kinases, for example in both the
cases of auto-phosphorylation or dephosphorylation the phosphor-
ylation mapping showed that there are sites which are on the ki-
nase domain itself and are accessible during E. coli expression,
but inaccessible during the equivalent in vitro experiment.
While all of the proteins in this particular study could be pro-
duced in a stable, monomeric, form without signiﬁcant aggregation
despite the high levels of phosphorylation, in many cases proteins
cannot be over-expressed in a soluble form except in the presence
of a co-expressed phosphatase (e.g. YopH for expression of tyrosine
kinases Fes [19] or Abl/Src [20]), and even when they are produced
in a soluble form the yield may be higher with phosphatase co-
expression as in the case of STK24 presented here. As discussedhere and elsewhere, this is now a well-knownmethod of producing
soluble protein for protein kinases which exert problematic activ-
ity such as phosphorylation-associated toxicity when expressed in
a heterologous system. The results presented here suggest that one
reason for the success of phosphatase co-expression in such cases
may be prevention of phosphorylation at sites that interfere with
protein folding. There are other potential explanations of these
observations such as co-expression of phosphatases reducing tox-
icity of the expressed target by removing undesirable phosphoryla-
tions that occur on essential endogenous proteins, and there may
be combinations of mechanisms, but our results give additional
support to the ﬁrst hypothesis.
It is interesting to speculate on why some proteins remain solu-
ble with extensive hyper-phosphorylation (such as PLK4 with up to
18 phosphorylations) while others cannot be produced in a soluble
form in the absence of phosphatase. One simple reason would be
the presence or absence of phosphorylationmotifs on internal sites.
However, the relative rates of protein folding and phosphorylation
and the absence of eukaryotic chaperones such as hsp90 in bacteria
could also be a factor; we have shown in this paper that the rate of
expression affects the phosphorylation level and a protein that folds
faster may be less susceptible to internal phosphorylation.
It is unlikely that phosphorylation sites that occur only during re-
combinant protein expression function as regulatory post-transla-
tional sites. However, it is interesting to note that a number of
kinases auto-phosphorylate during folding either in a chaperonin-
dependent or independent manner on sites that are not recognised
by fully folded protein [21,22]. Speciﬁcally, the dual speciﬁcity
kinases DYRK and GSK3 auto-activate on tyrosine residues. In our
study, we also identiﬁed auto-phosphorylation on tyrosine residues
for the kinase PLK4. Two of these tyrosines are located within the
activation segment (Tyr169 and Tyr177) suggesting that PLK4 may
share a similar activationmechanism as described for DYRK kinases.
StrikinglyTyr177wasalsoobserved in in vitro auto-phosphorylation
experiments and similarly toDYRKkinases this tyrosine couldnotbe
dephosphorylated by phosphatase treatment.
Although in some cases co-expression with phosphatase is the
only option, in others where kinases activate by auto-phosphoryla-
tion it may still be beneﬁcial to express the protein in the presence
of phosphatase, and subsequently perform the activation in vitro to
avoid the introduction of non-physiological phosphorylations. The
results presented here support this as an option that is available in
principle although its use would of course depend on the particular
protein of interest being suitable and on the type of study. For
obtaining fully active kinases, in many cases an upstream kinase
is required to provide the necessary phosphorylations.
In addition to the analysis of phosphorylation events, in this
study we provided expression protocols for nine human protein ki-
nases that have essential functions in cellular signalling. The re-
ported expression systems were the most efﬁcient ones from a
larger number of constructs that have been cloned and tested in
our laboratory. All of the constructs express soluble protein with-
out the addition of large protein tags to enhance solubility such
as glutathione-S-transferase. All of the proteins were puriﬁed by
a simple two-step puriﬁcation which yielded protein of sufﬁcient
purity for many types of experiment, and if required the expression
and puriﬁcation procedures could be optimised for higher yield,
higher purity or larger scale. We hope therefore that these expres-
sion protocols will facilitate further biochemical studies in the sig-
nalling ﬁeld that depends on efﬁcient systems for the generation of
stable recombinant proteins in economical bacterial host systems.Conﬂict of interest
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